Jimmy Hwang, MD
Medical Oncology · Charlotte, NCNPI 1487653911
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,970 of the $63,567 with a category attached, or 62.9%. It is spread thinly across 17 manufacturers, the largest accounting for just 16.6%.
Across 52 payments — averaging $1222.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$11K
- AstraZeneca$10K
- Boehringer Ingelheim International GmbH$7K
- E.r. Squibb & Sons, L.L.C.$6K
- Ipsen Biopharmaceuticals, Inc$6K
- Exelixis Inc.$5K
- plus $19K from 11 others
Across 153 payments — averaging $8082.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$263K
- E.r. Squibb & Sons, L.L.C.$243K
- AstraZeneca$196K
- Boehringer Ingelheim$173K
- Boehringer Ingelheim Pharma GmbH & Co.kg$140K
- Exelixis Inc.$93K
- plus $129K from 5 others
What the payments were for
- Consulting fees$19,88431%
- Speaking & faculty fees$39,97063%
- Travel & lodging$1,9303%
- Food & beverage$1,7143%
- Education$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 5 | $10,579 |
| AstraZeneca | 7 | $9,887 |
| Boehringer Ingelheim International GmbH | 2 | $6,941 |
| E.r. Squibb & Sons, L.L.C. | 3 | $6,307 |
| Ipsen Biopharmaceuticals, Inc | 4 | $6,181 |
| Exelixis Inc. | 9 | $4,537 |
| Astellas Pharma Global Development | 1 | $2,704 |
| Jazz Pharmaceuticals Inc. | 1 | $2,632 |
| Array Biopharma Inc | 1 | $2,520 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 6 | $2,390 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $2,040 |
| Eisai Inc. | 1 | $1,875 |
| Bayer | 4 | $1,758 |
| GSK | 1 | $1,600 |
| Deciphera Pharmaceuticals Inc. | 3 | $1,306 |
| Genentech USA, Inc. | 2 | $223 |
| Genentech, Inc. | 1 | $87 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$63,567 in reported general payments places this provider in the 85th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 14 | $279,582 |
| CreonLipase/Protease/Amylase | 28 | $42,345 |
| Imatinib Mesylate | 12 | $869 |
| Ondansetron Hcl | 35 | $227 |
| Prochlorperazine Maleate | 19 | $165 |
| Potassium Chloride | 13 | $106 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Charlotte
- David RizzieriCharlotte$714K
- Nilanjan GhoshCharlotte$510K
- Mohamed SalemCharlotte$396K
- Edward KimCharlotte$188K
- Kathryn MilehamCharlotte$110K
- Antoinette TanCharlotte$89K
- Ashley SumrallCharlotte$55K
- Obiageli OgbataCharlotte$26K
- Daniel CarrizosaCharlotte$20K
- Daniel HaggstromCharlotte$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.